Search Results for: 19

— First Granted Patent in Europe Directly Related to Ribaxamase, intended to Prevent C. difficile Infection, Antibiotic-Associated Diarrhea and the Emergence of Antibiotic-Resistant Organisms — ROCKVILLE, Md., July 12, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome announced today that the European Patent […]

— Ribaxamase Designed for the Prevention of C. difficile Infection, Antibiotic-Associated Diarrhea & the Emergence of Antibiotic-Resistant Organisms — — Oral Presentation Planned for ANAEROBE 2016 — ROCKVILLE, Md., July 7, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific

ROCKVILLE, Md., July 6, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases, announced today that Jeffrey Riley, President & Chief Executive Officer, is scheduled to present at the 2nd Annual Cantor Fitzgerald Annual Healthcare Conference being held July

— Phase 2 Clinical Trials Demonstrate Potential of SYN-010 to Reduce Abdominal Pain and Bloating, and Improve Stool Frequency and Quality of Life Scores without Severe Adverse Events in IBS-C Patients — — Results from Separate PK Study Demonstrate SYN-010 Avoids the Stomach and Releases Throughout the GI Tract in Healthy Volunteers — — Mark

— Mark Pimentel, MD, FRCP(C) to Review IBS-C Patient Data from Two SYN-010 Phase 2 Clinical Trials — — Conference Call Scheduled on Monday, May 23, 2016, at 8:30 a.m. (EDT) — ROCKVILLE, Md., May 17, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the

— SYN-004 Degraded IV Ceftriaxone in the Presence of a Proton Pump Inhibitor in the Gastrointestinal Tract without Affecting Antibiotic Levels in the Bloodstream — — Two Poster Presentations Planned for ASM Microbe 2016, Including Detailed Data from Two SYN-004 Phase 2a Open-Label Clinical Trials — ROCKVILLE, Md., May16, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE

— Company Expands Strategic Partnering Efforts of Late-Stage GI Microbiome-Focused Clinical Programs — ROCKVILLE, Md., May 11, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced Isaac J. Bright, MD, has joined the Company in the new position of Vice President,

— Appointment Reflects Company’s Late-Stage Clinical Focus and Plans to Prepare for Commercialization — ROCKVILLE, Md., May 9, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced Deb Mathews, PharmD, has joined the Company in the new position of Vice President,

— Positioned to Initiate Phase 3 Clinical Trial for SYN-010 for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in 2H 2016 — — Two SYN-010 Posters Scheduled for Presentation at Digestive Disease Week (DDW 2016), Including Additional Positive Results from Two Phase 2 Clinical Trials — — Conference Call Today, May 5, 2016,

— Conference Call Scheduled for Thursday, May 5, 2016 at 4:30 p.m. EDT — ROCKVILLE, Md., April, 26, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that the Company intends to release its operational highlights and financial results for the